# CGON catalysts: CG Oncology, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cgon/catalysts

> CG Oncology, Inc. (CGON) has 4 upcoming catalysts. The next is the cretostimogene grenadenorepvec topline data readout, Mar to Jun 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | CG Oncology, Inc. |
| Ticker | CGON (Nasdaq) |
| SEC CIK | 1991792 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/cgon |

## Cash runway

Cash $984.5M as of 2026-09-30; quarterly burn $47.7M; about 61.9 months of runway at that rate (XBRL company facts, accession 0001991792-26-000012).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [CORE-008 trial start](https://sec-api.dev/pdufa/core-008) | CGON |  | completed | "In October 2024, we initiated CORE-008 Cohort A, a Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without papillary disease and patients with only papillary disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)) |
| November 12, 2024 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/ck0001991792-ex99_1.htm)) |
| March 28, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-ex99_1.htm)) |
| May 13, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/ck0001991792-ex99_1.htm)) |
| 2H 2025 | [Cretostimogene topline data readout](https://sec-api.dev/pdufa/cretostimogene) | CGON |  | scheduled | "CORE-008 Cohort A (HR BCG-na&iuml;ve NMIBC): Topline data from the Phase 2 clinical trial of cretostimogene monotherapy anticipated in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-ex99_1.htm)) |
| 2H 2025 | [BOND-003 topline data readout](https://sec-api.dev/pdufa/bond-003) | CGON |  | scheduled | "The first patient has been dosed in BOND-003 Cohort P. We expect to report topline data from Cohort P in the second half of 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1991792/000119312524278472/d872865d424b4.htm)) |
| August 8, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/ck0001991792-ex99_1.htm)) |
| late 2025 | [CORE-008 topline data readout](https://sec-api.dev/pdufa/core-008) | CGON |  | scheduled | ""Looking ahead, further readouts are expected from our BOND-003 trial and the anticipated initiation of our Biologics License Application (BLA) submission, as well as the announcement of topline data from CORE-008 Cohort A expected before year-end."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-ex99_1.htm)) |
| Q4 2025 | [Cretostimogene NDA/BLA submission](https://sec-api.dev/pdufa/cretostimogene) | CGON | with HR NMIBC unresponsive to BCG | scheduled | ""We are eager to bring this innovative treatment to a broad range of NMIBC patients, and we are making great strides towards that goal as we prepare to initiate our BLA submission for cretostimogene in our initial indication for the treatment of patients with HR NMIBC unresponsive to BCG in the fourth quarter of this year."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000199179225000004/ck0001991792-ex99_1.htm)) |
| November 14, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-ex99_1.htm)) |
| 1H 2026 | [PIVOT-006 topline data readout](https://sec-api.dev/pdufa/pivot-006) | CGON |  | scheduled | "PIVOT-006 Topline Data Expected in 1H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526008329/ck0001991792-ex99_1.htm)) |
| February 27, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/ck0001991792-ex99_1.htm)) |
| May 8, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/ck0001991792-ex99_1.htm)) |
| August 6, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-ex99_1.htm)) |
| Nov 2026 | [PIVOT-006 topline data readout](https://sec-api.dev/pdufa/pivot-006) | CGON |  | scheduled | "•PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000011/cgon-20261106x8kexx991.htm)) |
| November 2026 | [Cretostimogene grenadenorepvec primary completion](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer | scheduled | "NCT06111235 (A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111235)) |
| Nov 2026 to Feb 2027 | [Cretostimogene grenadenorepvec topline data readout](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer | scheduled | "NCT06111235 (A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111235)) |
| November 6, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000011/cgon-20261106x8kexx991.htm)) |
| Mar to Jun 2027 | [Cretostimogene grenadenorepvec topline data readout](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | High-Risk Non-Muscle-Invasive Bladder Cancer | scheduled | "NCT06567743 (Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567743)) |
| March 2027 | [Cretostimogene grenadenorepvec primary completion](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | High-Risk Non-Muscle-Invasive Bladder Cancer | scheduled | "NCT06567743 (Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567743)) |
| Jun to Sep 2030 | [Cretostimogene grenadenorepvec topline data readout](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer | scheduled | "NCT04452591 (Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-16 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04452591)) |
| June 2030 | [Cretostimogene grenadenorepvec primary completion](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer | scheduled | "NCT04452591 (Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-16 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04452591)) |

## Drugs

- [BOND-003](https://sec-api.dev/pdufa/bond-003): 
- [CORE-008](https://sec-api.dev/pdufa/core-008): 
- [Cretostimogene](https://sec-api.dev/pdufa/cretostimogene): with hr nmibc unresponsive to bcg
- [Cretostimogene grenadenorepvec](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec): High-Risk Non-Muscle-Invasive Bladder Cancer, Non Muscle Invasive Bladder Cancer
- [PIVOT-006](https://sec-api.dev/pdufa/pivot-006): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cgon/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CGON catalysts: CG Oncology, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cgon/catalysts

```bibtex
@misc{secapidev_companies_cgon_catalysts_20261116,
  title        = {CGON catalysts: CG Oncology, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cgon/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cgon_catalysts_20261116","title":"CGON catalysts: CG Oncology, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cgon/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
